RevMed earns ASCO standing ovation as Akeso faces caution at the meeting
TL;DR Summary
STAT’s ASCO in 30 Seconds notes a rare standing ovation for RevMed at ASCO, while Akeso is treated with caution as the conference rolls on. The plenary has wrapped, but STAT will return with a final recap tomorrow; full article is gated behind STAT+.
- A standing ovation for RevMed, and caution for Akeso statnews.com
- BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDA statnews.com
- ASCO26 highlights: Ivonescimab's OS win, the RAS revolution, and more from Lilly, Pfizer, J&J FirstWord Pharma
- ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer Yahoo
- Misty Dawn Shields: Fabulous “Research to Practice” session on updates in Small Cell Lung Cancer Oncodaily
Reading Insights
Total Reads
0
Unique Readers
8
Time Saved
3 min
vs 3 min read
Condensed
92%
564 → 44 words
Want the full story? Read the original article
Read on statnews.com